Lisa King

• Selected, contracted, monitored and managed 15 key early development non-GLP nonclinical pharmacology and toxicology studies with Contract Research Organizations (CROs). • Prepared and coordinated review of study protocols, reports and other documents to ensure accuracy and timely completion of nonclinical studies. • Monitored study progress to ensure that study activities are consistent with the protocol and with the needs of the project. • Supervised the trafficking of study samples, data, and study documents between Sangamo, Contract Research Organization (CRO), or other outside collaborator. • Maintained records to ensure accurate sample inventory and traceability. • Trained in conducting GLP studies in compliance with current regulatory requirements. • Conducted and oversaw external of CRO facilities. • Maintained understanding and awareness of general in vivo AAV and gene therapy pharmacology and toxicology best practices • Adhered to good documentation practices; departmental procedures and safety requirements. • Represented the department by participating on project teams.

•Selected, contracted, monitored and managed 25 early research non-GLP nonclinical pharmacology and toxicology studies with Contract Research Organizations (CROs) • Prepared and/or coordinate review of study protocols, study reports and other study documents to ensure accuracy and timely completion of nonclinical studies. • Monitored study progress to ensure that study activities were consistent with the protocol and with the needs of the project. • Supervised the trafficking of study samples, data, and study documents between Sangamo, Contract Research Organization (CRO), or other outside collaborator. • Maintained records to ensure accurate sample inventory and traceability. • Trained in conducting GLP studies in compliance with current regulatory requirements. • Conducted and/or oversaw external CRO facilities. • Maintained understanding and awareness of general in vivo AAV and gene therapy pharmacology and toxicology best practices • Adhered to good documentation practices; departmental procedures and safety requirements. • Represented the department by participating on project teams.

•Selected, contracted, monitored and managed 75 early research non-GLP nonclinical pharmacology and toxicology studies with Contract Research Organizations (CROs) • Prepared and/or coordinate review of study protocols, study reports and other study documents to ensure accuracy and timely completion of nonclinical studies. • Monitored study progress to ensure that study activities were consistent with the protocol and with the needs of the project. • Supervised the trafficking of study samples, data, and study documents between Sangamo, Contract Research Organization (CRO), or other outside collaborator. • Maintained records to ensure accurate sample inventory and traceability. • Trained in conducting GLP studies in compliance with current regulatory requirements. • Conducted and/or oversaw external CRO facilities. • Maintained understanding and awareness of general in vivo AAV and gene therapy pharmacology and toxicology best practices • Adhered to good documentation practices; departmental procedures and safety requirements. • Represented the department by participating on project teams.

•Selected, contracted, monitored and managed 25 early research non-GLP nonclinical pharmacology and toxicology studies with Contract Research Organizations (CROs) • Prepared and/or coordinate review of study protocols, study reports and other study documents to ensure accuracy and timely completion of nonclinical studies. • Monitored study progress to ensure that study activities were consistent with the protocol and with the needs of the project. • Supervised the trafficking of study samples, data, and study documents between Sangamo, Contract Research Organization (CRO), or other outside collaborator. • Maintained records to ensure accurate sample inventory and traceability. • Trained in conducting GLP studies in compliance with current regulatory requirements. • Conducted and/or oversaw external CRO facilities. • Maintained understanding and awareness of general in vivo AAV and gene therapy pharmacology and toxicology best practices • Adhered to good documentation practices; departmental procedures and safety requirements. • Represented the department by participating on project teams.

•Developed molecular biology-based assays using Zinc Finger technology for genomic medicines •Supported clinical assays for the Phase 1/2 HIV clinical study using zinc finger nucleases (ZFNs) to disable the CCR5 gene in T lymphocytes and hematopoietic stem and progenitor cells (HSPCs), including Cel-1 nuclease, RT-qPCR-based, and flow cytometry. •Supported assays for the Phase 1/2 beta thalassemia clinical study using ZFNs to disable the BCL11A enhancer gene in HSPCs, including Western, peripheral cell and DNA isolation. •Developed ELISA-based AAV-specific assays for the Phase 1/2 Hemophilia A (Factor VIII) clinical study using recombinant AAV vector encoding a modified Factor 8 cDNA